Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(0.95)
# 3,683
Out of 4,868 analysts
137
Total ratings
27.5%
Success rate
-24.45%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $10 | $3.61 | +177.01% | 1 | Jun 18, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | $42 | $13.74 | +205.79% | 9 | Jun 17, 2025 | |
| LYRA Lyra Therapeutics | Maintains: Neutral | $2 → $16 | $10.68 | +49.81% | 8 | Jun 10, 2025 | |
| PHAT Phathom Pharmaceuticals | Reiterates: Buy | $20 | $10.90 | +83.49% | 10 | Jun 9, 2025 | |
| AKBA Akebia Therapeutics | Assumes: Buy | $8 | $3.56 | +124.72% | 1 | Jun 4, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $10 | $3.82 | +161.78% | 5 | May 29, 2025 | |
| UBX Unity Biotechnology | Downgrades: Neutral | $4 → $2 | $0.79 | +153.10% | 9 | May 27, 2025 | |
| TARS Tarsus Pharmaceuticals | Assumes: Buy | $72 | $41.06 | +75.35% | 1 | May 27, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $10 | $3.17 | +215.46% | 13 | May 19, 2025 | |
| ZBIO Zenas BioPharma | Reiterates: Buy | $30 | $9.39 | +219.49% | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $2.29 | +1,212.91% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $10.05 | +218.41% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $30.00 | +26.67% | 5 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $0.75 | +1,239.76% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.72 | +1,571.31% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $0.93 | +759.01% | 3 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.87 | +6.95% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 | $3.53 | -15.01% | 4 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.41 | -41.35% | 7 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $4.83 | -58.59% | 16 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $4.09 | +780.20% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $265.57 | -89.46% | 1 | Aug 22, 2023 |
Ardelyx
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $3.61
Upside: +177.01%
Mineralys Therapeutics
Jun 17, 2025
Reiterates: Buy
Price Target: $42
Current: $13.74
Upside: +205.79%
Lyra Therapeutics
Jun 10, 2025
Maintains: Neutral
Price Target: $2 → $16
Current: $10.68
Upside: +49.81%
Phathom Pharmaceuticals
Jun 9, 2025
Reiterates: Buy
Price Target: $20
Current: $10.90
Upside: +83.49%
Akebia Therapeutics
Jun 4, 2025
Assumes: Buy
Price Target: $8
Current: $3.56
Upside: +124.72%
DiaMedica Therapeutics
May 29, 2025
Reiterates: Buy
Price Target: $10
Current: $3.82
Upside: +161.78%
Unity Biotechnology
May 27, 2025
Downgrades: Neutral
Price Target: $4 → $2
Current: $0.79
Upside: +153.10%
Tarsus Pharmaceuticals
May 27, 2025
Assumes: Buy
Price Target: $72
Current: $41.06
Upside: +75.35%
Aldeyra Therapeutics
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $3.17
Upside: +215.46%
Zenas BioPharma
May 16, 2025
Reiterates: Buy
Price Target: $30
Current: $9.39
Upside: +219.49%
May 15, 2025
Reiterates: Buy
Price Target: $30
Current: $2.29
Upside: +1,212.91%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $10.05
Upside: +218.41%
May 8, 2025
Reiterates: Buy
Price Target: $38
Current: $30.00
Upside: +26.67%
May 1, 2025
Reiterates: Buy
Price Target: $10
Current: $0.75
Upside: +1,239.76%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $0.72
Upside: +1,571.31%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $0.93
Upside: +759.01%
Mar 31, 2025
Reiterates: Neutral
Price Target: $2
Current: $1.87
Upside: +6.95%
Mar 31, 2025
Reiterates: Neutral
Price Target: $3
Current: $3.53
Upside: -15.01%
Mar 25, 2025
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.41
Upside: -41.35%
Mar 21, 2025
Reiterates: Neutral
Price Target: $2
Current: $4.83
Upside: -58.59%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $4.09
Upside: +780.20%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $265.57
Upside: -89.46%